Phospho-NTRK1 (Ser791) Antibody

What is NTRK1 and why is its Ser791 phosphorylation site significant?

NTRK1 (Neurotrophic Tyrosine Kinase Receptor Type 1), also known as TrkA, is a high-affinity receptor for nerve growth factor (NGF) that plays crucial roles in neuronal development and function. The protein is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3, and neurotrophin-4/5, but not brain-derived neurotrophic factor (BDNF) .

The Ser791 phosphorylation site of NTRK1 is significant because:

• It is highly conserved across species, suggesting evolutionary importance

• It resides within a region critical for downstream signaling pathways

• Its phosphorylation status affects NTRK1's role in the nociceptive reception system and thermal regulation via sweating

• Known substrates for NTRK1 include SHC1, PI 3-kinase, and PLC-gamma-1, with phosphorylation potentially modulating these interactions

How do NTRK1 Ser791 phospho-antibodies differ from antibodies targeting other phosphorylation sites?

Phospho-NTRK1 (Ser791) antibodies:

• Specifically recognize the phosphorylated serine at position 791 within the specific motif (often P-V-Y-L-D sequence context)

• Are typically developed using synthetic phosphopeptides corresponding to amino acids surrounding Ser791

• Should not cross-react with unphosphorylated NTRK1 or other phosphorylation sites when properly validated

• Are distinct from Tyr791 phospho-antibodies, which recognize a different modification at the same position number

It's critical to note that literature contains references to both Ser791 and Tyr791 phosphorylation sites on NTRK1, which can lead to confusion. When designing experiments, verify the exact phosphorylation site and surrounding sequence recognized by your antibody.

What are the validated applications for Phospho-NTRK1 (Ser791) antibodies?

Based on current research literature, validated applications include:

The antibody has been successfully used to detect phosphorylated NTRK1 in human samples, with some antibodies also validated for mouse and rat samples .

What experimental controls should be included when using Phospho-NTRK1 (Ser791) antibody?

For rigorous experimental design, include the following controls:

• Positive control: Lysates from cells treated with NGF or other known activators of NTRK1 phosphorylation

• Negative control:

  • Unstimulated cells (baseline phosphorylation)

  • Cells treated with NTRK1 inhibitors

  • Samples where phosphatases have been used to remove phosphorylation

• Antibody validation controls:

  • Blocking peptide competition assay using the immunizing phosphopeptide

  • Comparison with a total NTRK1 antibody on the same samples

• Specificity controls:

  • Use of NTRK1 knockout/knockdown samples

  • Samples expressing Ser791Ala mutant NTRK1 that cannot be phosphorylated at this site

These controls will help distinguish specific from non-specific signals and validate phosphorylation-dependent recognition.

How does NTRK1 Ser791 phosphorylation relate to its role in oncogenic signaling pathways?

NTRK1 participates in several oncogenic signaling pathways:

• YAP oncogenic function: NTRK1 has been identified as a positive regulator of YAP oncogenic function. Studies using mouse xenograft models demonstrated that NTRK1 knockdown inhibited tumor growth and reduced YAP protein levels in NTRK1 knockdown tumors .

• ERK activation: NTRK1 activates ERK1 through either SHC1- or PLC-gamma-1-dependent signaling pathways, which are involved in cancer cell proliferation and survival .

To study these pathways:

• Use phospho-specific antibodies against both NTRK1 and downstream effectors

• Compare phosphorylation patterns in normal versus cancer cells

• Correlate NTRK1 Ser791 phosphorylation with activation of oncogenic pathways

• Employ genetic approaches (shRNA, CRISPR) to disrupt NTRK1 expression or function

What is the mechanistic difference between phosphorylation at Ser791 versus Tyr791 in NTRK1?

This is an important distinction that causes confusion in the literature:

Ser791 phosphorylation:

• Appears to be involved in regulating NTRK1 signaling through modulation of protein-protein interactions

• May affect the nociceptive reception system and thermal regulation

Tyr791 phosphorylation:

• Occurs within the sequence context P-V-Y(p)-L-D

• Located in the amino acid range 747-796 of human TrkA

• Potentially involved in different signaling cascades compared to Ser791 phosphorylation

When designing experiments:

• Carefully verify which phosphorylation site your antibody recognizes

• Use site-directed mutagenesis (Ser791Ala or Tyr791Phe) to distinguish the functional roles

• Consider phospho-proteomics approaches to identify all phosphorylation events simultaneously

What are the most common pitfalls when using Phospho-NTRK1 (Ser791) antibodies?

Common challenges and their solutions include:

• Low signal-to-noise ratio:

  • Increase antibody concentration (within manufacturer recommendations)

  • Optimize blocking conditions (5% BSA often works better than milk for phospho-antibodies)

  • Use phosphatase inhibitors during sample preparation

  • Consider enhanced chemiluminescence detection systems

• Cross-reactivity issues:

  • Verify antibody specificity with blocking peptides

  • Include appropriate knockout/knockdown controls

  • Perform parallel experiments with total NTRK1 antibody

• Variable results between experiments:

  • Standardize cell stimulation conditions that induce phosphorylation

  • Maintain consistent lysis buffer composition with phosphatase inhibitors

  • Store antibody according to manufacturer recommendations (typically at -20°C)

  • Avoid repeated freeze-thaw cycles of antibody

How can NTRK1 Ser791 phosphorylation be distinguished from Raptor Ser791 phosphorylation in research contexts?

An important technical consideration is that both NTRK1 and Raptor contain Ser791 phosphorylation sites, but they are entirely different proteins with distinct functions:

Distinguishing approaches:

• Immunoprecipitation strategy:

  • Immunoprecipitate using total NTRK1 or Raptor antibodies first

  • Then probe with phospho-specific antibodies for confirmation

• Size discrimination:

  • NTRK1 and Raptor have different molecular weights (NTRK1: ~140 kDa; Raptor: ~150 kDa)

  • Use appropriate molecular weight markers and running conditions in Western blots

• Context-specific controls:

  • PKA is known to phosphorylate Raptor at Ser791

  • NGF stimulation primarily affects NTRK1 phosphorylation

  • Use pathway-specific activators and inhibitors for discrimination

• Genetic approaches:

  • Use site-directed mutagenesis (S791A) in either protein

  • Knockdown/knockout of NTRK1 or Raptor to confirm specificity

In studies of both proteins, clearly document which protein's phosphorylation is being targeted to avoid confusion in the literature.

How does NTRK1 Ser791 phosphorylation impact neurodegenerative disease research?

NTRK1's crucial role in neuronal development suggests potential implications for neurodegenerative diseases:

• Research applications:

  • Monitor NTRK1 Ser791 phosphorylation status in Alzheimer's or Parkinson's disease models

  • Correlate phosphorylation with neuronal survival and function

  • Investigate therapeutic approaches targeting NTRK1 phosphorylation

• Methodological approaches:

  • Use Phospho-NTRK1 (Ser791) antibodies in post-mortem tissue studies

  • Develop phosphorylation-specific assays for clinical samples

  • Create neuron-specific conditional phospho-mimetic or phospho-deficient models

• Technical considerations:

  • Combine with other markers of neuronal health

  • Account for post-mortem changes in phosphorylation status

  • Use appropriate fixation methods to preserve phospho-epitopes

What is the role of NTRK1 Ser791 phosphorylation in cancer therapy resistance mechanisms?

As NTRK1 has been implicated in oncogenic signaling, its phosphorylation status may affect therapy responses:

• Research applications:

  • Monitor Ser791 phosphorylation in response to NTRK inhibitor therapy

  • Investigate whether phosphorylation status predicts treatment response

  • Determine if combination therapies targeting both NTRK1 and its phosphorylation provide synergistic effects

• Experimental approaches:

  • Develop phosphorylation-specific cell-based assays for drug screening

  • Use xenograft models with manipulated NTRK1 phosphorylation sites

  • Correlate phosphorylation with activation of alternative survival pathways